Skip to main content
. Author manuscript; available in PMC: 2018 Sep 25.
Published in final edited form as: Sci Transl Med. 2017 Oct 4;9(410):eaan8184. doi: 10.1126/scitranslmed.aan8184

Fig. 2.

Fig. 2.

Study design and pharmacokinetics of SMZAb cocktail administration to Indian rhesus macaques. (A) We administered a cocktail containing the three nmAbs, SMZAbs 1, 2, and 5 at a dose of 20 mg kg−1 each to four rhesus macaques (Group 1). A control group (Group 2) received the human CB1 isotype control at a dose of 60 mg kg−1 total. All animals were challenged with 1,000 PFU of ZIKV Rio U-1 2016 one day post mAb administration. Serum was collected at the indicated time points for viral load, neutralization, IgG, and IgM measurements. (A) Serum levels of recombinant Abs were determined by ELISA. Antibody level values for each SMZAb cocktail (blue) or control mAb (open symbols) animal. (C) Median values for the Group 1 (blue) and Group 2 (open symbols). (D) ZIKV-neutralizing activity in serum post mAb infusion was determined by FRNT. Median ZIKV-foci-neutralization percentage values for each SMZAb cocktail (blue) or control mAb (open symbols) animal. (E) Median values for the Group 1 (blue) and Group 2 (open symbols).